Danburstotug by Sorrento Therapeutics for Cervical Cancer: Likelihood of Approval

Danburstotug is under clinical development by Sorrento Therapeutics and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III drugs for Cervical Cancer have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Danburstotug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Danburstotug overview

STIA-1015 is under development for the treatment of solid tumors including colon cancer, gastric adenocarcinoma, esophageal squamous cell carcinoma, advanced urothelial carcinoma, in-transit metastatic melanoma, hepatocellular carcinoma and relapsed or refractory extranodal NK/T Cell Lymphoma. It is administered through intravenous and intralymphatic route. The drug candidate is a monoclonal antibody targeting PD-L1 (programmed cell death 1 ligand 1).

Sorrento Therapeutics overview

Sorrento Therapeutics (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is also investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.

For a complete picture of Danburstotug’s drug-specific PTSR and LoA scores, buy the report here.